<p>LifeStance Health Group (LFST) 的股價在公司宣佈盈利能力改善和全年調整後息税折舊攤銷前利潤（Adjusted EBITDA）預測超出華爾街預期後上漲。這一消息得到了紐約聯邦儲備銀行行長關於利率的鼓舞人心的評論的進一步支持。</p>
<p>查看我們對 LifeStance Health Group 的最新分析。</p>
<p>LifeStance Health Group 的股價在過去一個月內急劇反彈，漲幅超過 23%，因為對盈利能力和利率的樂觀情緒推動了市場動能。儘管股東在過去三年內的總回報接近 36%，但最近一年的總股東回報卻為 -15%。這突顯出復甦仍在穩步進行中，但顯示出對未來增長的 renewed interest。</p>
<p>如果今天醫療股的動能引起了你的注意，這可能是通過我們的免費完整列表發現新競爭者的完美時機。</p>
<p>股價已經反彈；然而，考慮到混合的盈利指引和持續的市場樂觀情緒，投資者不禁想知道 LifeStance Health Group 是否真的被低估，或者最新的漲幅是否已經反映了未來的增長潛力。</p>
<h2>最受歡迎的敍述：23.6% 被低估</h2>
<p>LifeStance Health Group 最新的收盤價低於該敍述的公允價值估計，暗示如果增長假設得以實現，未來可能會有上漲空間。該敍述強調了快速擴張的故事，併為未來幾年的潛在轉型奠定了基礎。</p>
<blockquote>
<p>&#34;對人工智能和數字技術平台（如自動化收入週期工具、患者參與系統和增強護理匹配）的投資預計將推動運營槓桿，降低行政成本，提高臨牀醫生的生產力。這些變化可能會在長期內帶來更高的淨利潤率和增加的收益。&#34;</p>
</blockquote>
<p>閲讀完整敍述。</p>
<p>想知道是什麼推動了這些大規模估值判斷嗎？發現這一樂觀前景背後的關鍵增長驅動因素、利潤預測和一個令人驚訝的財務飛躍。完整的敍述將所有要素連接起來——找出推動這一潛在轉機的假設。</p>
<p><strong>結果：公允價值為 $8.43（被低估）</strong></p>
<p>完整閲讀敍述，瞭解預測背後的原因。</p>
<p>然而，競爭加劇和持續的報銷壓力可能會限制 LifeStance 的增長潛力，如果行業動態在未來幾年意外變化。</p>
<p>瞭解 LifeStance Health Group 敍述的關鍵風險。</p>
<h2>另一種觀點：倍數説了什麼？</h2>
<p>超越未來現金流假設，LifeStance Health Group 的市銷率為 1.8 倍，明顯高於同行和更廣泛的醫療行業平均水平 1.3 倍。與公允比率（同樣為 1.3 倍）相比，目前的估值似乎偏高，並引發了市場預期變化時的上漲風險問題。投資者是否為預期的增長支付了過高的價格，還是溢價反映了公司的獨特前景？</p>
<p>查看數字對這一價格的看法——在我們的估值分析中瞭解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e421b528-b565-4b30-a932-6e525e138818/chart/ps-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e421b528-b565-4b30-a932-6e525e138818/chart/ps-multiple-vs-industry"/></p>
<p>納斯達克：LFST 市銷率截至 2025 年 11 月</p>
<h2>自己構建 LifeStance Health Group 的敍述</h2>
<p>如果你想深入挖掘或從不同角度看待問題，你可以在幾分鐘內塑造自己的 LifeStance Health Group 故事。按照你的方式進行。</p>
<p>一個好的起點是我們的分析，強調投資者對 LifeStance Health Group 的 3 個關鍵回報的樂觀情緒。</p>
<h2>尋找更多投資想法？</h2>
<p>通過精心挑選符合你策略的股票，抓住新興機會。利用這些強大且易於使用的篩選工具，獲得你所需的優勢。</p>
<ul>
<li>通過抓住科技領域的動能，解鎖快速增長潛力，關注這 26 只人工智能便士股。</li>
<li>通過關注這些 15 只收益率超過 3% 的股息股票，捕捉穩定的收入來源。</li>
<li>通過投資這些 81 只加密安全和區塊鏈股票，站在創新的前沿。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也不考慮你的目標或財務狀況。我們旨在為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

LFST

<p>LifeStance Health 集團的股票在宣佈盈利能力改善和樂觀的 EBITDA 預測後上漲。該股票在一個月內反彈了 23%，受益於利率樂觀情緒。儘管三年回報率為 36%，但一年回報率為-15%。市場認為該公司被低估了 23.6%，合理價值為 8.43 美元。對人工智能和數字平台的投資預計將提升利潤率。然而，競爭和報銷壓力帶來了風險。市銷率高於行業平均水平，引發了估值擔憂</p>

<p>LifeStance Health Group (LFST) shares climbed after the company announced better profitability and a full-year Adjusted EBITDA forecast above Wall Street expectations. This was further supported by encouraging comments on interest rates from the New York Federal Reserve President.</p>
<div class="lb-trans"><p>LifeStance Health Group (LFST) 的股價在公司宣佈盈利能力改善和全年調整後息税折舊攤銷前利潤（Adjusted EBITDA）預測超出華爾街預期後上漲。這一消息得到了紐約聯邦儲備銀行行長關於利率的鼓舞人心的評論的進一步支持。</p>
</div><p>See our latest analysis for LifeStance Health Group.</p>
<div class="lb-trans"><p>查看我們對 LifeStance Health Group 的最新分析。</p>
</div><p>LifeStance Health Group’s shares have rebounded sharply, jumping over 23% in the past month as optimism about profitability and interest rates fueled momentum. While shareholders have seen a 3-year total return of nearly 36%, the recent 1-year total shareholder return lags at -15%. This highlights a recovery that is still gaining its footing but shows signs of renewed interest around future growth.</p>
<div class="lb-trans"><p>LifeStance Health Group 的股價在過去一個月內急劇反彈，漲幅超過 23%，因為對盈利能力和利率的樂觀情緒推動了市場動能。儘管股東在過去三年內的總回報接近 36%，但最近一年的總股東回報卻為 -15%。這突顯出復甦仍在穩步進行中，但顯示出對未來增長的 renewed interest。</p>
</div><p>If today's momentum in healthcare stocks caught your attention, this could be the perfect moment to discover new contenders through our See the full list for free.</p>
<div class="lb-trans"><p>如果今天醫療股的動能引起了你的注意，這可能是通過我們的免費完整列表發現新競爭者的完美時機。</p>
</div><p>The share price has rebounded; however, with mixed earnings guidance and ongoing market optimism, investors are left wondering whether LifeStance Health Group is genuinely undervalued or if the latest gains already reflect future growth potential.</p>
<div class="lb-trans"><p>股價已經反彈；然而，考慮到混合的盈利指引和持續的市場樂觀情緒，投資者不禁想知道 LifeStance Health Group 是否真的被低估，或者最新的漲幅是否已經反映了未來的增長潛力。</p>
</div><h2>Most Popular Narrative: 23.6% Undervalued</h2>
<div class="lb-trans"><h2>最受歡迎的敍述：23.6% 被低估</h2>
</div><p>LifeStance Health Group’s latest closing price sits below the narrative’s fair value estimate, signaling possible upside ahead if growth assumptions are realized. The narrative highlights a rapid expansion story and sets the stage for a potentially transformative few years.</p>
<div class="lb-trans"><p>LifeStance Health Group 最新的收盤價低於該敍述的公允價值估計，暗示如果增長假設得以實現，未來可能會有上漲空間。該敍述強調了快速擴張的故事，併為未來幾年的潛在轉型奠定了基礎。</p>
</div><blockquote>
<p>&#34;Investments in AI and digital technology platforms (such as automated revenue cycle tools, patient engagement systems, and enhanced care matching) are expected to drive operating leverage, reduce administrative costs, and improve clinician productivity. These changes may result in higher net margins and increased earnings over the longer term.&#34;</p>
</blockquote>
<div class="lb-trans"><blockquote>
<p>&#34;對人工智能和數字技術平台（如自動化收入週期工具、患者參與系統和增強護理匹配）的投資預計將推動運營槓桿，降低行政成本，提高臨牀醫生的生產力。這些變化可能會在長期內帶來更高的淨利潤率和增加的收益。&#34;</p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>閲讀完整敍述。</p>
</div><p>Want to know what powers these big valuation calls? Discover the pivotal growth drivers, margin forecasts, and one surprising financial leap behind this bullish outlook. The full narrative connects all the dots—find the assumptions driving this potential turnaround.</p>
<div class="lb-trans"><p>想知道是什麼推動了這些大規模估值判斷嗎？發現這一樂觀前景背後的關鍵增長驅動因素、利潤預測和一個令人驚訝的財務飛躍。完整的敍述將所有要素連接起來——找出推動這一潛在轉機的假設。</p>
</div><p><strong>Result: Fair Value of $8.43 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>結果：公允價值為 $8.43（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整閲讀敍述，瞭解預測背後的原因。</p>
</div><p>However, intensifying competition and ongoing reimbursement pressure could limit LifeStance’s growth potential if industry dynamics shift unexpectedly in the coming years.</p>
<div class="lb-trans"><p>然而，競爭加劇和持續的報銷壓力可能會限制 LifeStance 的增長潛力，如果行業動態在未來幾年意外變化。</p>
</div><p>Find out about the key risks to this LifeStance Health Group narrative.</p>
<div class="lb-trans"><p>瞭解 LifeStance Health Group 敍述的關鍵風險。</p>
</div><h2>Another View: What Do Multiples Say?</h2>
<div class="lb-trans"><h2>另一種觀點：倍數説了什麼？</h2>
</div><p>Looking beyond future cash flow assumptions, LifeStance Health Group trades on a Price-to-Sales ratio of 1.8x, noticeably higher than both peers and the broader healthcare industry average of 1.3x. Compared to the fair ratio, also at 1.3x, the current valuation appears rich and raises questions about upside risks if market expectations shift. Are investors paying too much for anticipated growth, or does a premium reflect the company’s unique prospects?</p>
<div class="lb-trans"><p>超越未來現金流假設，LifeStance Health Group 的市銷率為 1.8 倍，明顯高於同行和更廣泛的醫療行業平均水平 1.3 倍。與公允比率（同樣為 1.3 倍）相比，目前的估值似乎偏高，並引發了市場預期變化時的上漲風險問題。投資者是否為預期的增長支付了過高的價格，還是溢價反映了公司的獨特前景？</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看數字對這一價格的看法——在我們的估值分析中瞭解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e421b528-b565-4b30-a932-6e525e138818/chart/ps-multiple-vs-industry" alt="" original-src="https://images.simplywall.st/company/e421b528-b565-4b30-a932-6e525e138818/chart/ps-multiple-vs-industry"/></p>
<p>NasdaqGS:LFST PS Ratio as at Nov 2025</p>
<div class="lb-trans"><p>納斯達克：LFST 市銷率截至 2025 年 11 月</p>
</div><h2>Build Your Own LifeStance Health Group Narrative</h2>
<div class="lb-trans"><h2>自己構建 LifeStance Health Group 的敍述</h2>
</div><p>If you want to dig deeper or see things from a different angle, you can shape your own LifeStance Health Group story in just a few minutes. Do it your way</p>
<div class="lb-trans"><p>如果你想深入挖掘或從不同角度看待問題，你可以在幾分鐘內塑造自己的 LifeStance Health Group 故事。按照你的方式進行。</p>
</div><p>A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding LifeStance Health Group.</p>
<div class="lb-trans"><p>一個好的起點是我們的分析，強調投資者對 LifeStance Health Group 的 3 個關鍵回報的樂觀情緒。</p>
</div><h2>Looking for More Investment Ideas?</h2>
<div class="lb-trans"><h2>尋找更多投資想法？</h2>
</div><p>Capitalize on emerging opportunities by handpicking stocks tailored to your strategy. Gain the edge you need with these powerful, easy-to-use screeners.</p>
<div class="lb-trans"><p>通過精心挑選符合你策略的股票，抓住新興機會。利用這些強大且易於使用的篩選工具，獲得你所需的優勢。</p>
</div><ul>
<li>Unlock rapid growth potential by seizing the momentum in tech with these 26 AI penny stocks.</li>
<li>Capture resilient income streams by targeting market leaders that pay attractive yields through these 15 dividend stocks with yields &gt; 3%.</li>
<li>Position yourself at the forefront of innovation by tapping into breakthroughs in cryptographic security with these 81 cryptocurrency and blockchain stocks.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過抓住科技領域的動能，解鎖快速增長潛力，關注這 26 只人工智能便士股。</li>
<li>通過關注這些 15 只收益率超過 3% 的股息股票，捕捉穩定的收入來源。</li>
<li>通過投資這些 81 只加密安全和區塊鏈股票，站在創新的前沿。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也不考慮你的目標或財務狀況。我們旨在為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

分析 LifeStance Health Group（LFST）在盈利能力改善和指導方針調整後的估值